

oioanoinsider

ITALIA

Published by the Italian Trade Commission of Los Angeles www.ltaltrade.com

In this Issue

BIO 2009 Preview: Italy's **Biotech Sector Endures Despite** Global Recession

It's Time to Celebrate... Italy's Life Sciences Industry Marks Two Important Milestones

Message from Paola Bellusci Trade Commissioner

Investment & Collaboration Spotlight

Italian and US Researchers Pioneer Epigenetic Profiling

Bio3 Research and Two Californian Companies Team Up to Fight Cardiovascular Disease

Innovation Briefs

Mount Vesuvius' Sulfurous Steam May Treat Dysfunction

BIO 2009 Italian Pavilion Exhibitors and Networking Events

News and Commentary About Italy's Biotech and Nanotech Industries


BIO 2009 Preview: Italy's Biotech Sector Endures Despite Global Recession

Undeterred by the current economic crisis, Italy's best and most creative biotechnology firms and research institutions once again have big plans in store for the annual BIO International Convention, which will take place in Atlanta May 18-21.

As in past years, dozens of leading-edge companies will exhibit in the modern Italian

tions and investment opportunities... all possessing a uniquely Italian sense of originality and style.

Italy's biotech sector continues to grow rapidly despite the troubling global economy.



Study for the Italian Trade Commission. New York by Cedar-Technomic

This growth is due to many factors, Pavilion to unveil innovations, collabora- including an established critical mass of labor, knowledge, intrastructure and investment, as well as a substantial commitment by Italy's leaders to make biotech industry growth a national priority. Government at all levels continues to implement new policies and reforms, from

(Continued on Page 3)

It's Time to Celebrate... Italy's Life Sciences Industry Marks Two Important Milestones

As Italy's biotech sector prepares to impress before an international audience at BIO 2009, it is also gearing up to celebrate two important life sciences milestones.

The first milestone is the 50th anniversary of one of the great discoveries in the fight against infectious diseases. It was in 1959 that **Dr. Piero Sensi** and

Message from Paola Bellusci Trade Commissioner

How can we take our readers close to Italy's latest technological accomplishments and opportunities? That is the question we ask ourselves when we plan a new issue of our newsletter and, each time, the possibilities are many, because so much happens in Italian biotech and nanotech business and research from one quarter to the next.

In this special BIO 2009 issue of the Bio-Nano Insider, we look at how Italy's biotech sector is faring in the midst of the current economic downturn. We also celebrate anniversaries for two important milestones in the development of Italy's life sciences industry. We then bring you up-to-speed on the latest news involving biotech investment, collaboration and scientific innovation, and wrap-up the issue with a list of BIO 2009 Italian Pavilion exhibitors and events.

As it has in years past, the Italian Trade Commission besides having the Pavilion at BIO 2009 in Atlanta (May 18-21) will host a networking event at the W Atlanta Midtown to showcase Italy's world-class biotech innovations.

We hope to see you in Atlanta!

Paola Bellusci

Trade Commissioner

his colleagues at Gruppo Lepetit S.p.A. in Milan discovered *Rifomycin* – a group of powerful antibiotics still used today as primary therapy to treat tuberculosis, leprosy and MAC (mycobacterium avium complex) infections. The Rifomycin group includes the derivatives such as Rifampicin, which Piero Sensi created almost 10 years later as the single most effective treatment against TB still in use today. According to the World Health Organization, tuberculosis kills nearly 2 million people and infects 9 million every year and it is considered one of the most important world health emergencies.

The second milestone is the 100th birthday of Italian neurologist Rita Levi Montalcini, who received the 1986 Nobel Prize in Medicine along with her colleague Stanley Cohen for their discovery of nerve growth factor (NGF). When they are secreted, NGF protein molecules induce the differentiation and survival of particular target neurons or nerve cells. They are found in high levels among people who have recently fallen in love. They are also linked to Alzheimer's and Parkinson's diseases, cancer and birth defects.

Dr. Levi-Montalcini's long and distinguished career began in 1930 at the

University of Turin Medical School. After graduating, she worked under the direction of Prof. Giuseppe Levi until her career was temporarily cut short by Mussolini's 1938 Manifesto of Race and the introduction of laws barring Jews from academic and professional careers.

She spent three decades at Washington University in St. Louis, where she became a full professor and established a research unit in Rome. She also spent nearly 20 years at Italy's famed CNR (National Research Council), where she directed

Consortium Extends Italy's Dominance in Antibiotic Research



NAICONS Laboratory in Milan

Italy's well-earned reputation for innovation in the field of antibiotics research has gained a substantial boost with the establishment of NAICONS (New Anti Infectives CONSortium). Based in Milan, the public-private partnership is dedicated to the discovery of new anti-infective compounds to address unmet medical needs and the growing threat of multi-drug resistant infections. Partners in the consortium include the Renato Dulbecco Foundation, Associazione CISI and leadingedge pharmaceutical companies NeED Pharma and KtedoGen.

For more information: Dr. Daniela Jabes, djabes@naicons.com

Italian Researchers Expand Arsenal in Fight Against TB

An all female team of researchers at the University of Pavia near Milan, is helping develop a new class of drugs called benzothiazin (BTZ) to fight tuberculosis. One drug in particular – known as BTZ043 – has demonstrated effectiveness in treating even otherwise drug-resistant forms of the disease. This discovery, led by Prof. Giovanna Riccardi, was published in the journal Science on the eve of TB World Day on March 24th.

For more information: Prof. Giovanna Riccardi, riccardi@ipvgen.inpv.it

the Research Center for Neurobiology and the Laboratory of Cellular Biology. In 2001, she founded the Rome-based

> European Brain Research Institute (EBRI) and was named a Senator for Life by the Italian Republic. Her foundation so far has awarded nearly 7,000 scholarships to young African women.

> She is still very active in research and in politics, enjoying great esteem in Italy and

abroad. As a Senator, she defended the teaching of evolution in schools when, in 2004, the then education minister, wanted to remove it from school curricula.

Dr. Levi-Montalcini is the oldest living Nobel laureate, and the first ever to reach 100!



Rita Levi Montalcini

(Continued from Page 1)

more favorable intellectual property laws to tax relief and incentives to promote R&D and new start-ups.

The latest industry report from Blossom & Company and Assobiotec titled "Biotechnology in Italy 2009. The Financial Perspective", shows the number of Italian biotech companies has more than tripled in the past five years (from 83 to 260). Overall revenues for Italian biotech firms in 2008 exceeded \$20 billion, which represents an 18% year-over-year increase. The sector employs roughly 41,000, more than 20 percent of whom are engaged directly in R&D activities.

In terms of trade with the US, biotech imports from Italy have been on the rise growing at 17% on average between 2004 and 2008 to reach \$2.5 billion.

Most of the companies in Italy's biotech sector are focused on applications in healthcare, with special emphasis in oncology, immunology, cardiology and infectious diseases. These firms have more than 250 products in development, including 55 in Phase III clinical trial.

Such companies are eager and wellpositioned to pursue collaboration opportunities with their counterparts in the
US, and the timing could not be better.
While Italian firms have abundant scientific know-how, many could benefit from
US-style business development practices
to bridge the gap between research and
commercial applications. US experts in
life science tech transfer and early-stage
funding are finding that Italy can be a very
welcoming home away from home.

To further highlight opportunities for US companies interested in connecting with Italy's biotech, this year, at the Italian Trade Commission's networking event "Connecting with Italian Biotech: New Policies, New Opportunities", Giuseppe Martini, Director of the Life Sciences Department at the Italian National Research Council (CNR) will outline a wide range of Italy-USA successful research collaborations (see page 4).

Italian and US Researchers Pioneer Epigenetic Profiling

A team of US and Italian researchers has developed a new epigenetic screening technology that improves molecularbased disease diagnosis, and may hold the key to more personalized therapy. It employs high-throughput DNA sequencing that enables doctors to determine a patient's epigenetic profile in just 3-4 days, while using a very small sample of cells. The project was led by Prof. Saverio Minucci at the FIRC Institute of Molecular Oncology/European Institute of Oncology (IFOM-IEO) in Milan, which is recognized as one of the world's leading centers for epigenetic research. His team worked closely with U.S. colleagues at the J. Craig Venter Institute in Maryland and Sangamo BioSciences in Virginia, and published their results in the international journal Development Cell. Epigenetic research is an increasingly important branch of molecular biology that focuses on the mechanisms regulating gene expression, and how such alternations can lead to diseases such as cancer.

For more information: Prof. Saverio Minucci, saverio.minucci@ifom-ieo-campus.it

Bio3 Research and Two Californian Companies Team Up to Fight Cardiovascular Disease

Milan-based Bio3 Research S.r.I. SynGen and Protelica (formerly ProtElix, Inc.) both based in Hayward, California have entered an agreement to collaborate on R&D involving mimic-antibodies that could potentially be used to help fight heart disease. The agreement merges Bio3 Research's intellectual property and marketing expertise with Proletica's core antibody mimics platform and SynGen's innovative nucleaic acid solutions. The goal is to discover and develop cheaper, more effective protein drug antagonists focused on HMGB1 - a biological target identified as a primary factor contributing to several cardiovascular disorders. The three companies estimate the global market for such therapeutics at about \$35 billion. Their collaboration is the result of Bio3 Research's participation in the Italian Pavilion at BIO 2008.

For more information: www.bio3research.com

Innovation Briefs

Mount Vesuvius' Sulfurous Steam May Treat Dysfunction

Italian researchers have reported that the compound responsible for the stench of rotten eggs may help create a new class of drugs to treat erectile dysfunction. Prof. Giuseppe Cirino and his colleagues at the University of Naples Federico II have found enzymes that produce hydrogen sulphide (H2S) in human penile tissue, and that injecting the compound directly into such tissue can cause blood vessels to relax and



Mount Vesuvius

produce an erection. Similar research on another gas – nitric oxide (NO) led to the creation of Viagra. About one-third of men with erectile dysfunction do not respond to currently available drugs. The results of Prof. Cirino's study were published in the journal Proceedings of the National Academy of Sciences.

For more information: Prof. Giuseppe Cirino, cirino@unina.it



Connecting with Italian Biotech: New Policies, New Opportunities

May 19, 2009 W Atlanta Midtown, Altitude (27th Floor) 188 14th Street NE, Atlanta 30361

7:00 PM - 7:30 PM Guest Arrival and Registration

7:30 PM - 7:35 PM Welcome

Paola Bellusci, Trade Commissioner Italian Trade Commission, Los Angeles

7:35 PM = 7:45 PM Current Trends in Italian Biotechnology

Leonardo Vingiani, Director, Assobiotec

7:45 PM - 8:00 PM The View from Washington

Cole Werble, Senior Executive Editor

FDC-Windhover

8:00 PM - 8:15 PM Inbound-Outbound Financing

Nicola Fiordalisi and Gino Serra

Partners, Bryan Cave LLP

8:15 PM - 8:30 PM Italian-American Success Stories

Giuseppe Martini, Director, Life Sciences Department

Italian National Research Council (CNR)

8:30 PM - 8:35 PM Closing Remarks

Mark Trusheim, President, Co-Bio Consulting

8:30 PM - 10:00 PM Italian Buffet Dinner and Networking



In partnership with:





Italian Pavilion

BOOTH #4301 May 18-21, 2009

Georgia World Congress Center



Organizations:

Italian Trade Commission www.italtrade.com

Assobiotec www.assobiotec.it

National Committee for Biosafety, Biotechnology and Life Sciences www.palazzochigi.it/

biotecnologie www.osservatoriobiotec.it

Regione Lombardia Promos, Special Agency of the Milan Chamber of Commerce-Member Companies & Organizations:

Regione Lombardia www.regione.lombardia.it

Promos - Special Agency of the Milan Chamber of Commerce www.promositaly.com

Areta International www.aretaint.com

Artenergy S.r.I. www.chem-med.eu

CMC & QS S.r.l. www.cmcgs.com

Emmeplus SpA

Fondazione Centro San Raffaele www.fondazionesanraffaele.it

Fondazione Istituto Insubrico di Ricerca per la Vita www.ricercaperlavita.it

Ho.p.e www.hopekit.com Need Pharmaceuticals www.needpharma.com

Nexthera Biosciences S.r.I. www.nexthera.com

Parco Tecnologico Padano www.tecnoparco.org

Pharma & Biotech Advisors S.r.I.

www.pharmaebiotech.com

TOP (Transgenic Operative Products) S.r.I. www.top-mice.com

Sardegna Ricerche – The Technology Park of Sardinia - Member Companies & Organizations:

Sardegna Ricerche – The Technology Park of Sardinia www.sardegnaricerche.it

Bcs Biotech S.p.A www.biocs.it

Biofarmitalia S.p.A. www.biofarmitalia.it

Bioflag www.bioflag.it

Bio-Ker S.r.I.

Crs4 www.crs4.it

Edx Diagnostics S.r.l. www.edxdia.com

Pharmaness www.pharmaness.it

Proteotech S.r.l. www.proteotech.it Shardna Life Sciences www.shardna.it

Torino Chamber of Commerce - Member Companies & Organizations:

Torino Chamber of Commerce www.to.camcom.it

Centro Estero per l'Internazionalizzazione S.C.P.A. www.centroestero.org

Bioindustry Park del Canavese S.p.A. www.bioindustrypark.eu

Bioman S.r.I. www.bioman.it

CCS Aosta S.r.I. www.micosat.it

Nanovector S.r.l. www.nanovector.it

Spider Biotech S.r.l. www.spiderbiotech.com

Other Italian Exhibitors:

Italian National Research Council – Department of Life Sciences www.life.cnr.it

Fondazione Toscana Life Sciences www.toscanalifesciences.org

Menarini Biotech Srl www.menarini.com

Molmed SpA www.molmed.com

ABOUT THE ITALIAN TRADE COMMISSION

The Italian Trade Commission, also known as the Italian Institute of Foreign Trade, is the government agency responsible for the promotion of trade, business opportunities, and industrial cooperation between Italian and foreign companies, as well as research centers and universities.

The Italian Trade Commission supports the international activities of Italian firms, including their presence and consolidation in foreign markets. It operates more than a hundred offices in eighty-four countries, including five in the United States of America: New York, Los Angeles, Chicago, Atlanta, and Miami. The Italian Trade Commission's promotional activities

are financed both by government funds, provided by

the Italian Ministry for Economic Development, and by private contributions by companies that benefit from its activities and services. These include the exchange of information, assistance in marketing planning, promotion, multilateral cooperation, and training.

U.S. biotechnology and nanotechnology companies are encouraged to contact the Italian Trade Commission in Los Angeles to learn what Italy has to offer in terms of products, services and investment/collaboration opportunities.

In addition, U.S. companies can find out where to meet Italian companies in the U.S. at trade shows, workshops and conferences, as well as in Italy via trade missions and other promotional activities.



Contact In the U.S.A.

Italian Trade Commission
1801 Avenue of the Stars, Suite 700
Los Angeles, California 90067
(323) 879 0950
losangeles@losangeles.ice.it
www.italtrade.com

www.biotechinitaly.com